What's new? Log in Free sign up

Filing search / Kineta, Inc. / "Department of"

Search information

Kineta, Inc.

Companies

"Department of"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

97 results

Newest first Best match first

KANT Kineta, Inc.

Quarterly report

(the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance … the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule

8 Aug 24

4:00pm

KANT Kineta, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

of Listing. On May 23, 2024, Kineta, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff

KANT Kineta, Inc.

Quarterly report

(the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq … received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company

15 May 24

4:05pm

KANT Kineta, Inc.

Entry into a Material Definitive Agreement

Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2

KANT Kineta, Inc.

, the U.S. Department of Health and Human Services (“HHS”) and the CMS issued various rules that are expected to impact, among others, price reductions from … regulatory and governmental authorities, Department of Justice, Department of Health and Human Services’ (“HHS”) Office of Inspector General, state

21 Mar 24

4:06pm

fcxu76dornpq2d1

Quarterly report

3 Nov 23

4:04pm

m4f053b8 x07eko8o

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Prospectus supplement for primary offering

r4x4dsvtpsdgkyx

jpp3hpqwrhw utkx8

Quarterly report

11 Aug 23

4:07pm

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

31 Mar 23

4:05pm

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Quarterly report

14 Nov 22

8:44am

Prospectus supplement

Prev
1
2
3
4
5
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.